These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 19277978)

  • 1. Human embryonic stem cell technologies and drug discovery.
    Jensen J; Hyllner J; Björquist P
    J Cell Physiol; 2009 Jun; 219(3):513-9. PubMed ID: 19277978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The application of human embryonic stem cell technologies to drug discovery.
    Sartipy P; Björquist P; Strehl R; Hyllner J
    Drug Discov Today; 2007 Sep; 12(17-18):688-99. PubMed ID: 17826681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiomyocytes derived from human embryonic stem cells - characteristics and utility for drug discovery.
    Steel D; Hyllner J; Sartipy P
    Curr Opin Drug Discov Devel; 2009 Jan; 12(1):133-40. PubMed ID: 19152222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human embryonic stem cells: current technologies and emerging industrial applications.
    Améen C; Strehl R; Björquist P; Lindahl A; Hyllner J; Sartipy P
    Crit Rev Oncol Hematol; 2008 Jan; 65(1):54-80. PubMed ID: 17689256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood group ABO antigen expression in human embryonic stem cells and in differentiated hepatocyte- and cardiomyocyte-like cells.
    Mölne J; Björquist P; Andersson K; Diswall M; Jeppsson A; Strokan V; Rydberg L; Breimer ME
    Transplantation; 2008 Nov; 86(10):1407-13. PubMed ID: 19034011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of human embryonic stem cell-derived mesoderm and cardiac cells using size-specified aggregates in an oxygen-controlled bioreactor.
    Niebruegge S; Bauwens CL; Peerani R; Thavandiran N; Masse S; Sevaptisidis E; Nanthakumar K; Woodhouse K; Husain M; Kumacheva E; Zandstra PW
    Biotechnol Bioeng; 2009 Feb; 102(2):493-507. PubMed ID: 18767184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient differentiation of hepatocytes from human embryonic stem cells exhibiting markers recapitulating liver development in vivo.
    Hay DC; Zhao D; Fletcher J; Hewitt ZA; McLean D; Urruticoechea-Uriguen A; Black JR; Elcombe C; Ross JA; Wolf R; Cui W
    Stem Cells; 2008 Apr; 26(4):894-902. PubMed ID: 18238852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors to consider in the use of stem cells for pharmaceutic drug development and for chemical safety assessment.
    Trosko JE; Chang CC
    Toxicology; 2010 Mar; 270(1):18-34. PubMed ID: 19948204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiomyocytes from human pluripotent stem cells in regenerative medicine and drug discovery.
    Braam SR; Passier R; Mummery CL
    Trends Pharmacol Sci; 2009 Oct; 30(10):536-45. PubMed ID: 19762090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Xeno-free derivation and culture of human embryonic stem cells: current status, problems and challenges.
    Lei T; Jacob S; Ajil-Zaraa I; Dubuisson JB; Irion O; Jaconi M; Feki A
    Cell Res; 2007 Aug; 17(8):682-8. PubMed ID: 17667917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protocols for cardiac differentiation of embryonic stem cells.
    Pucéat M
    Methods; 2008 Jun; 45(2):168-71. PubMed ID: 18593613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impacts of recent advances in cardiovascular regenerative medicine on clinical therapies and drug discovery.
    Murata M; Tohyama S; Fukuda K
    Pharmacol Ther; 2010 May; 126(2):109-18. PubMed ID: 20156482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioprocessing of embryonic stem cells for drug discovery.
    Thomson H
    Trends Biotechnol; 2007 May; 25(5):224-30. PubMed ID: 17379341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First steps in establishing a developmental toxicity test method based on human embryonic stem cells.
    Adler S; Pellizzer C; Hareng L; Hartung T; Bremer S
    Toxicol In Vitro; 2008 Feb; 22(1):200-11. PubMed ID: 17961973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Propensity of human embryonic stem cell lines during early stage of lineage specification controls their terminal differentiation into mature cell types.
    Pal R; Totey S; Mamidi MK; Bhat VS; Totey S
    Exp Biol Med (Maywood); 2009 Oct; 234(10):1230-43. PubMed ID: 19546356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Embryonic stem (ES) cell-derived cardiomyocytes: a good candidate for cell therapy applications.
    Pal R
    Cell Biol Int; 2009 Mar; 33(3):325-36. PubMed ID: 19121644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can human embryonic stem cells contribute to the discovery of safer and more effective drugs?
    Cezar GG
    Curr Opin Chem Biol; 2007 Aug; 11(4):405-9. PubMed ID: 17662644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospects for pluripotent stem cell-derived cardiomyocytes in cardiac cell therapy and as disease models.
    Freund C; Mummery CL
    J Cell Biochem; 2009 Jul; 107(4):592-9. PubMed ID: 19449339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Embryonic stem cell test in screening of medicine and other chemicals].
    Zhao Q; Xu J
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2005 Feb; 22(1):181-4. PubMed ID: 15762145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The biological and ethical basis of the use of human embryonic stem cells for in vitro test systems or cell therapy.
    Leist M; Bremer S; Brundin P; Hescheler J; Kirkeby A; Krause KH; Poerzgen P; Puceat M; Schmidt M; Schrattenholz A; Zak NB; Hentze H
    ALTEX; 2008; 25(3):163-90. PubMed ID: 18841314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.